372 related articles for article (PubMed ID: 17195414)
21. Value of anti-modified citrullinated vimentin and third-generation anti-cyclic citrullinated peptide compared with second-generation anti-cyclic citrullinated peptide and rheumatoid factor in predicting disease outcome in undifferentiated arthritis and rheumatoid arthritis.
van der Linden MP; van der Woude D; Ioan-Facsinay A; Levarht EW; Stoeken-Rijsbergen G; Huizinga TW; Toes RE; van der Helm-van Mil AH
Arthritis Rheum; 2009 Aug; 60(8):2232-41. PubMed ID: 19644872
[TBL] [Abstract][Full Text] [Related]
22. Rheumatoid factor and antibodies to cyclic citrullinated Peptide differentiate rheumatoid arthritis from undifferentiated polyarthritis in patients with early arthritis.
Jansen AL; van der Horst-Bruinsma I; van Schaardenburg D; van de Stadt RJ; de Koning MH; Dijkmans BA
J Rheumatol; 2002 Oct; 29(10):2074-6. PubMed ID: 12375314
[TBL] [Abstract][Full Text] [Related]
23. Antibodies to Cyclic Citrullinated Peptides in Patients With Juvenile Idiopathic Arthritis and Patients With Rheumatoid Arthritis: Shared Expression of the Inherently Autoreactive 9G4 Idiotype.
Peckham H; Cambridge G; Bourke L; Sen D; Radziszewska A; Leandro M; Ioannou Y
Arthritis Rheumatol; 2017 Jul; 69(7):1387-1395. PubMed ID: 28380667
[TBL] [Abstract][Full Text] [Related]
24. Autoantibody profile in rheumatoid arthritis during long-term infliximab treatment.
Bobbio-Pallavicini F; Alpini C; Caporali R; Avalle S; Bugatti S; Montecucco C
Arthritis Res Ther; 2004; 6(3):R264-72. PubMed ID: 15142273
[TBL] [Abstract][Full Text] [Related]
25. Anti-cyclic citrullinated peptide antibody isotypes in rheumatoid arthritis: association with disease duration, rheumatoid factor production and the presence of shared epitope.
Lakos G; Soós L; Fekete A; Szabó Z; Zeher M; Horváth IF; Dankó K; Kapitány A; Gyetvai A; Szegedi G; Szekanecz Z
Clin Exp Rheumatol; 2008; 26(2):253-60. PubMed ID: 18565246
[TBL] [Abstract][Full Text] [Related]
26. High IgA rheumatoid factor levels are associated with poor clinical response to tumour necrosis factor alpha inhibitors in rheumatoid arthritis.
Bobbio-Pallavicini F; Caporali R; Alpini C; Avalle S; Epis OM; Klersy C; Montecucco C
Ann Rheum Dis; 2007 Mar; 66(3):302-7. PubMed ID: 17079248
[TBL] [Abstract][Full Text] [Related]
27. The predictive value of rheumatoid factor isotypes, anti-cyclic citrullinated peptide antibodies, and antineutrophil cytoplasmic antibodies for mortality in patients with rheumatoid arthritis.
Sihvonen S; Korpela M; Mustila A; Mustonen J
J Rheumatol; 2005 Nov; 32(11):2089-94. PubMed ID: 16265684
[TBL] [Abstract][Full Text] [Related]
28. Anti-carbamylated protein antibodies are present in arthralgia patients and predict the development of rheumatoid arthritis.
Shi J; van de Stadt LA; Levarht EW; Huizinga TW; Toes RE; Trouw LA; van Schaardenburg D
Arthritis Rheum; 2013 Apr; 65(4):911-5. PubMed ID: 23279976
[TBL] [Abstract][Full Text] [Related]
29. Anti-cyclic citrullinated peptide antibody and rheumatoid factor isotypes in Iranian patients with rheumatoid arthritis: evaluation of clinical value and association with disease activity.
Shakiba Y; Koopah S; Jamshidi AR; Amirzargar AA; Massoud A; Kiani A; Nicknam MH; Nazari B; Nikbin B
Iran J Allergy Asthma Immunol; 2014 Jun; 13(3):147-56. PubMed ID: 24659118
[TBL] [Abstract][Full Text] [Related]
30. Diagnostic utility of anti-cyclic citrullinated peptide antibodies for very early rheumatoid arthritis.
Matsui T; Shimada K; Ozawa N; Hayakawa H; Hagiwara F; Nakayama H; Sugii S; Ozawa Y; Tohma S
J Rheumatol; 2006 Dec; 33(12):2390-7. PubMed ID: 16924694
[TBL] [Abstract][Full Text] [Related]
31. The prevalence of rheumatoid factor isotypes and anti-cyclic citrullinated peptides in Malaysian rheumatoid arthritis patients.
Gomez EL; Gun SC; Somnath SD; D'Souza B; Lim AL; Chinna K; Radhakrishnan AK
Int J Rheum Dis; 2011 Feb; 14(1):12-7. PubMed ID: 21303477
[TBL] [Abstract][Full Text] [Related]
32. [Cyclic citrullinated peptide antibodies (anti-CCP) together with some other parameters used for serologic diagnosis of rheumatoid arthritis].
Us D; Gülmez D; Hasçelik G
Mikrobiyol Bul; 2003; 37(2-3):163-70. PubMed ID: 14593899
[TBL] [Abstract][Full Text] [Related]
33. Assessment of antibodies to double-stranded DNA induced in rheumatoid arthritis patients following treatment with infliximab, a monoclonal antibody to tumor necrosis factor alpha: findings in open-label and randomized placebo-controlled trials.
Charles PJ; Smeenk RJ; De Jong J; Feldmann M; Maini RN
Arthritis Rheum; 2000 Nov; 43(11):2383-90. PubMed ID: 11083258
[TBL] [Abstract][Full Text] [Related]
34. Absence of cyclic citrullinated peptide antibody in nonarthritic patients with chronic hepatitis C infection.
Lienesch D; Morris R; Metzger A; Debuys P; Sherman K
J Rheumatol; 2005 Mar; 32(3):489-93. PubMed ID: 15742441
[TBL] [Abstract][Full Text] [Related]
35. Antibodies to porphyromonas gingivalis are associated with anticitrullinated protein antibodies in patients with rheumatoid arthritis and their relatives.
Hitchon CA; Chandad F; Ferucci ED; Willemze A; Ioan-Facsinay A; van der Woude D; Markland J; Robinson D; Elias B; Newkirk M; Toes RM; Huizinga TW; El-Gabalawy HS
J Rheumatol; 2010 Jun; 37(6):1105-12. PubMed ID: 20436074
[TBL] [Abstract][Full Text] [Related]
36. Autoantibodies in rheumatoid arthritis: association with severity of disease in established RA.
Agrawal S; Misra R; Aggarwal A
Clin Rheumatol; 2007 Feb; 26(2):201-4. PubMed ID: 16572283
[TBL] [Abstract][Full Text] [Related]
37. Diagnostic and clinical value of anti-cyclic citrullinated peptide antibodies compared with rheumatoid factor isotypes in rheumatoid arthritis.
Vallbracht I; Rieber J; Oppermann M; Förger F; Siebert U; Helmke K
Ann Rheum Dis; 2004 Sep; 63(9):1079-84. PubMed ID: 15308516
[TBL] [Abstract][Full Text] [Related]
38. An exploratory study to determine whether infliximab modifies levels of rheumatoid factor and antibodies to cyclic citrullinated peptides in rheumatoid arthritis patients.
Martínez-Estupiñán L; Hernández-Flórez D; Janta I; Ovalles-Bonilla JG; Nieto JC; González-Fernández CM; Del Río T; Monteagudo I; López-Longo FJ; Naredo E; Valor L
Clin Exp Rheumatol; 2018; 36(1):88-93. PubMed ID: 28850020
[TBL] [Abstract][Full Text] [Related]
39. Repeated anticitrullinated protein antibody and rheumatoid factor assessment is not necessary in early arthritis: results from the ESPOIR cohort.
Gossec L; Paternotte S; Combe B; Meyer O; Dougados M
J Rheumatol; 2014 Jan; 41(1):41-6. PubMed ID: 24241481
[TBL] [Abstract][Full Text] [Related]
40. Adalimumab clinical efficacy is associated with rheumatoid factor and anti-cyclic citrullinated peptide antibody titer reduction: a one-year prospective study.
Atzeni F; Sarzi-Puttini P; Dell' Acqua D; de Portu S; Cecchini G; Cruini C; Carrabba M; Meroni PL
Arthritis Res Ther; 2006; 8(1):R3. PubMed ID: 16356192
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
